DK1212060T3 - Anvendelse af nikotin eller derivater heraf samt L-DOPA i et lægemiddel til behandling af neurologiske sygdomme, især Parkinsons sygdom - Google Patents

Anvendelse af nikotin eller derivater heraf samt L-DOPA i et lægemiddel til behandling af neurologiske sygdomme, især Parkinsons sygdom

Info

Publication number
DK1212060T3
DK1212060T3 DK00960782T DK00960782T DK1212060T3 DK 1212060 T3 DK1212060 T3 DK 1212060T3 DK 00960782 T DK00960782 T DK 00960782T DK 00960782 T DK00960782 T DK 00960782T DK 1212060 T3 DK1212060 T3 DK 1212060T3
Authority
DK
Denmark
Prior art keywords
dopa
drug
nicotine
disease
derivatives
Prior art date
Application number
DK00960782T
Other languages
English (en)
Inventor
Pierre Cesaro
Gabriel Villafane
Original Assignee
Assist Publ Hopitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assist Publ Hopitaux De Paris filed Critical Assist Publ Hopitaux De Paris
Application granted granted Critical
Publication of DK1212060T3 publication Critical patent/DK1212060T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK00960782T 1999-09-02 2000-09-01 Anvendelse af nikotin eller derivater heraf samt L-DOPA i et lægemiddel til behandling af neurologiske sygdomme, især Parkinsons sygdom DK1212060T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9911029A FR2798065B1 (fr) 1999-09-02 1999-09-02 Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson
PCT/FR2000/002428 WO2001015696A1 (fr) 1999-09-02 2000-09-01 Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson

Publications (1)

Publication Number Publication Date
DK1212060T3 true DK1212060T3 (da) 2005-08-15

Family

ID=9549506

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00960782T DK1212060T3 (da) 1999-09-02 2000-09-01 Anvendelse af nikotin eller derivater heraf samt L-DOPA i et lægemiddel til behandling af neurologiske sygdomme, især Parkinsons sygdom

Country Status (10)

Country Link
US (1) US6911475B1 (da)
EP (1) EP1212060B1 (da)
AT (1) ATE292969T1 (da)
CA (1) CA2383509C (da)
DE (1) DE60019436T2 (da)
DK (1) DK1212060T3 (da)
ES (1) ES2241651T3 (da)
FR (1) FR2798065B1 (da)
PT (1) PT1212060E (da)
WO (1) WO2001015696A1 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69912808T2 (de) 1999-12-08 2004-09-30 Centre National De La Recherche Scientifique (C.N.R.S.) Verwendung von Hymenialdisin und dessen Derivaten zur Herstellung therapeutischer Mittel
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
CA2418135C (en) * 2000-08-03 2011-09-20 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
KR100421585B1 (ko) 2001-10-25 2004-03-09 한국전자통신연구원 시간분할 듀플렉스 시스템에서 이동국의 셀 탐색 시스템및 그 방법
DE10338174A1 (de) 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
US7387788B1 (en) 2003-10-10 2008-06-17 Antares Pharma Ipl Ag Pharmaceutical compositions of nicotine and methods of use thereof
CA2538856C (en) * 2003-10-10 2010-06-29 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
US20070191815A1 (en) 2004-09-13 2007-08-16 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
US7257577B2 (en) * 2004-05-07 2007-08-14 International Business Machines Corporation System, method and service for ranking search results using a modular scoring system
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
WO2007124250A2 (en) 2006-04-21 2007-11-01 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
KR100699582B1 (ko) 2005-07-11 2007-03-23 삼성전기주식회사 출력 버퍼회로
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
EP1977746B8 (en) * 2007-04-02 2014-09-24 Parkinson's Institute Methods and compositions for reduction of side effects of therapeutic treatments
AU2011203482B2 (en) * 2007-04-02 2014-09-04 Parkinson's Institute Methods and compositions for reduction of side effects of therapeutic treatments
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
US10105487B2 (en) 2013-01-24 2018-10-23 Chrono Therapeutics Inc. Optimized bio-synchronous bioactive agent delivery system
US9463186B2 (en) 2013-04-15 2016-10-11 Northwestern University Treatment for dopaminergic disorders
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 薬剤送達方法及びシステム
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
US10292977B2 (en) 2016-04-11 2019-05-21 Neurocea, LLC Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
US10143687B2 (en) 2016-04-11 2018-12-04 Neurocea, LLC Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
AU2019279884B2 (en) 2018-05-29 2025-01-30 Morningside Venture Investments Limited Drug delivery methods and systems
JP2022507660A (ja) 2018-11-16 2022-01-18 モーニングサイド ベンチャー インベストメンツ リミテッド 温度によって調節される経皮薬剤送達システム

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242935A (en) 1992-03-06 1993-09-07 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5232933A (en) * 1992-05-21 1993-08-03 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
DE60019436D1 (de) 2005-05-19
CA2383509A1 (fr) 2001-03-08
US6911475B1 (en) 2005-06-28
EP1212060A1 (fr) 2002-06-12
WO2001015696A1 (fr) 2001-03-08
DE60019436T2 (de) 2006-02-02
PT1212060E (pt) 2005-08-31
FR2798065A1 (fr) 2001-03-09
FR2798065B1 (fr) 2003-09-05
ATE292969T1 (de) 2005-04-15
EP1212060B1 (fr) 2005-04-13
ES2241651T3 (es) 2005-11-01
CA2383509C (fr) 2012-08-14

Similar Documents

Publication Publication Date Title
ATE292969T1 (de) Verwendung von nikotin oder derivaten und l-dopa zur behandlung von neurologischen krankheiten, insbesonder morbus parkinson
NL970006I1 (nl) Gebruik van indolon-derivaten voor het bereiden van geneesmiddelen ter behandeling van de ziekte vanParkinson.
EP0513702A3 (en) Melatonin derivaties for use in the therapy of sleep disorders and in pre-anaesthetic medication
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
CA2114014A1 (en) Advanced Drug Delivery System and Method of Treating Psychiatric, Neurological and Other Disorders with Carbamazepine
CY1111088T1 (el) Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση
WO2001001973A8 (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
WO2001039762A3 (en) Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system
GEP20043303B (en) Polycycloalkylpurines as Adenosine Receptor Antagonists
BG103521A (en) Substituted pyrimidinon and pyridon compounds and methods for their application
DE69329400D1 (de) L-Dopa Ester enthaltende Zusammensetzung
PL339946A1 (en) Drug preparation in the form of a prolonged drug release tablet for treating parkinsonism
JP2002522485A5 (da)
MX9805588A (es) Administracion oral de cantidades efectivas de formas de acido hialuronico.
PL370529A1 (en) Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug
GB2285219B (en) Use of norastemizole for the treatment of allergic disorders
EP1201246A3 (en) Use of Thrombopoietin as a medicament for the therapy and prevention of thrombocytopenia
AR023185A1 (es) Tratamiento de cancer mejorado con temozolomida
Wise Sertraline as a treatment for premature ejaculation.
KR970005283A (ko) 심근경색발생 후의 환자를 처치하기 위한 서트랄린의 용도
EP1632235A3 (en) Use of highly selective norepinephrine reuptake inhibitors for the treatment of mental disorders
Myers et al. Nocturnal cataclysms with myoclonus: a new side effect of clomipramine.
HUP9701606A2 (hu) Szulbutiamin alkalmazása bizonyos pszichomotoros és pszichointellektuális rendellenességek kezelésére használható gyógyszerkészítmények előállítására
JPS57167922A (en) Psychotropic drug
KR930019207A (ko) 카르니틴 결핍 hiv-혈청양성 환자 치료용 l-카르니틴의 용도